Currently, Chimerix Inc [CMRX] is trading at $1.24, up 2.90%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CMRX shares have gain 4.20% over the last week, with a monthly amount glided 35.80%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Chimerix to Present at TD Cowen 44th Annual Health Care Conference. In a post published today on Yahoo Finance, Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a Targeted Oncology Panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET.
From an analyst’s perspective:
Chimerix Inc [NASDAQ: CMRX] stock has seen the most recent analyst activity on May 23, 2023, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $7. Previously, CapitalOne started tracking the stock with Overweight rating on September 07, 2022, and set its price target to $7. On April 29, 2021, Maxim Group initiated with a Buy rating and assigned a price target of $20 on the stock. Wedbush initiated its recommendation with a Outperform and recommended $21 as its price target on March 31, 2021. Jefferies started tracking with a Buy rating for this stock on March 31, 2021, and assigned it a price target of $21. In a note dated February 14, 2018, JP Morgan downgraded an Underweight rating on this stock.
This stock has fluctuated between a low of $0.88 and a high of $1.77 over the last 52 weeks. Chimerix Inc [NASDAQ: CMRX] shares were valued at $1.24 at the most recent close of the market.
Analyzing the CMRX fundamentals
Trailing Twelve Months sales for Chimerix Inc [NASDAQ:CMRX] were 1.13M which represents -99.97% decline. Gross Profit Margin for this corporation currently stands at -13.93% with Operating Profit Margin at -84.72%, Pretax Profit Margin comes in at -74.97%, and Net Profit Margin reading is -72.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.35 and Total Capital is -0.46. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1867 points at the first support level, and at 1.1333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2967, and for the 2nd resistance point, it is at 1.3533.
Chimerix Inc [CMRX] reported earnings per share of -$0.27 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.23/share, meaning a difference of -$0.04 and a surprise factor of -17.40%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.21 per share as compared to estimates of -$0.24 per share, a difference of $0.03 representing a surprise of 12.50%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Chimerix Inc [NASDAQ:CMRX] is 12.93. Also, the Quick Ratio is 12.93, while the Cash Ratio stands at 0.91. Considering the valuation of this stock, the price to sales ratio is 97.54, the price to book ratio is 0.53.
Transactions by insiders
Recent insider trading involved Jakeman David, VP OF FINANCE AND ACCOUNTING, that happened on Feb 14 when 2660.0 shares were sold. CHIEF FINANCIAL OFFICER, LaSpaluto Michelle completed a deal on Feb 14 to sell 1940.0 shares. Meanwhile, PRESIDENT AND CEO Andriole Michael T. sold 1744.0 shares on Feb 14.
